Refractory Acute Myeloid Leukemia Clinical Trials

74 recruitingLast updated: June 26, 2026

There are 74 actively recruiting refractory acute myeloid leukemia clinical trials across 7 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, Duarte, California, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


Refractory Acute Myeloid Leukemia Trials at a Glance

74 actively recruiting trials for refractory acute myeloid leukemia are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 52 trials, with the heaviest enrollment activity in Houston, Duarte, and Columbus. Lead sponsors running refractory acute myeloid leukemia studies include M.D. Anderson Cancer Center, City of Hope Medical Center, and Fred Hutchinson Cancer Center.

Browse refractory acute myeloid leukemia trials by phase

Treatments under study

About Refractory Acute Myeloid Leukemia Clinical Trials

Looking for clinical trials for Refractory Acute Myeloid Leukemia? There are currently 47 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Acute Myeloid Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled18 locationsNCT06714591
Recruiting
Phase 1

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+2 more
Vanderbilt-Ingram Cancer Center60 enrolled2 locationsNCT06399640
Recruiting
Phase 1

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid Leukemia+2 more
Memorial Sloan Kettering Cancer Center15 enrolled7 locationsNCT06017258
Recruiting
Phase 1Phase 2

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center75 enrolled1 locationNCT03128034
Recruiting
Phase 1

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)47 enrolled7 locationsNCT07012044
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1

A Study of CRD3874-SI in People With Leukemia

Acute Myeloid LeukemiaAMLRefractory Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center24 enrolled7 locationsNCT07661095
Recruiting
Phase 1

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center12 enrolled1 locationNCT07025564
Recruiting
Phase 1

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center30 enrolled1 locationNCT05263284
Recruiting

Individualized AML Treatment

Relapsed/Refractory Acute Myeloid Leukemia (AML)
City of Hope Medical Center18 enrolled1 locationNCT07613385
Recruiting
Phase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 2

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Phase 1

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled22 locationsNCT06484062
Recruiting
Phase 1Phase 2

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04047641
Recruiting
Phase 1Phase 2

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center42 enrolled1 locationNCT05010122
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute26 enrolled1 locationNCT06871410
Recruiting
Phase 1

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center12 enrolled1 locationNCT06763341
Recruiting
Phase 1Phase 2

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center84 enrolled1 locationNCT04774393
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295